CRISPR Therapeutics AG

-$1.80 (-3.1%)
Closing Price on July 24, 2024

CRSP Chart and Intraday Price

CRSP Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 6,723.12M USD
Shares Outstanding 80,276,000
CRISPR Therapeutics AG is at the forefront of gene editing, pioneering treatments for serious diseases through its CRISPR/Cas9 technology. This innovative approach allows for precise DNA modifications, offering hope in areas like hemoglobinopathies, immune-oncology, autoimmune diseases, and type 1 diabetes. Its leading therapy, CASGEVY, aims to transform care for patients with severe blood disorders through gene-edited cell therapy. Additionally, the company is developing cutting-edge CAR T cell therapies and in vivo gene editing solutions, working in strategic partnerships to advance its mission of curing complex diseases.

CRSP Articles

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re...
Imagine this: you walk into a hospital for a procedure. You expect a long, traditional surgery with a lengthy recovery. But what if, instead of the scalpel, you could invest in a company with the...
Why did Ginkgo Bioworks CEO Jason Kelly chop 20 million shares from his stake in the company? Is no turnaround for the shares coming?
Wednesday's top analyst upgrades and downgrades included Abbott Laboratories, Boston Scientific, ChargePoint, Coinbase Global, Dollar General, Equitrans Midstream, Ford, Hasbro, Johnson & Johnson,...
Friday's top analyst upgrades and downgrades included American Airlines, Broadcom, Chevron, DraftKings, Enphase Energy, EOG Resources, Exxon Mobil, First Solar, Hertz Global, LyondellBasell...
Barclays recently issued a few calls across multiple industries picking a couple winners and a couple losers.
Tuesday's additional top analyst upgrades and downgrades were on Bed Bath & Beyond, Clorox, CRISPR Therapeutics, LivePerson, Nike, Palantir Technologies, Tyson Foods and more.
One big Wall Street name thinks it has found a big winner in this gene-editing company, and the stock could benefit greatly going forward.
Thursday's additional top analyst upgrades and downgrades included American Tower, Coinbase, Snowflake, Southwest and more.
Wednesday's top analyst upgrades and downgrades included Albemarle, Camping World, eBay, EOG Resources, Etsy, Global Payments, IMAX, JPMorgan Chase, MetLife, Otis Worldwide, Salesforce, Wayfair and...
Thursday's top analyst upgrades and downgrades included Alcon, Array Technologies, AZEK, Boeing, Capital One Financial, Coinbase Global, Corning, Electronic Arts, Harley-Davidson, ON Semiconductor,...
Thursday's top analyst upgrades and downgrades included Airbnb, Alcoa, Beyond Meat, Fidelity National Information Services, Marriott International, Monster Beverage, Paramount Global, Shopify, Spirit...
Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these...
A couple of Cathie Wood's ARK Invest exchange-traded funds bought nearly 60,000 shares of CRISPR Therapeutics on December 29 for $4.6 million.
Tuesday afternoon's top analyst upgrades and downgrades included Alibaba, Apple, AstraZeneca, Canopy Growth, CNX Resources, Murphy Oil, Ross Stores and Tesla.